EMA Authorised: Advagraf (tacrolimus) — Astellas Pharma Europe BV

View source ↗

Summary

Advagraf (tacrolimus) by Astellas Pharma Europe BV has been authorised for use in the EU for graft rejection indications.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Graft Rejection

Drugs mentioned

• Advagraf (tacrolimus)

Snippet

Status: Authorised. Therapeutic area: Graft Rejection. MAH: Astellas Pharma Europe BV. Decision date: 12/02/2025